1 / 10

Resectable disease Stage III Patients

NSCLC. Preoperative CT. Resectable disease Stage III Patients. Stage IIIA Preoperative CT Less competition but opportunity to take: NAVELBINE GEMZAR TAXOL TAXOTERE. NSCLC Main drugs. 91% (N 1 ) 87% (N 2 ). 78% (N 0 ) 76% (N 1 ). 100. 90. 66%. 62%. 80. 70. 39%. 60. 50.

maxine
Download Presentation

Resectable disease Stage III Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NSCLC Preoperative CT Resectable disease Stage III Patients

  2. Stage IIIA Preoperative CTLess competition but opportunity to take: NAVELBINE GEMZAR TAXOL TAXOTERE NSCLCMain drugs

  3. 91% (N1) 87% (N2 ) 78% (N0) 76% (N1) 100 90 66% 62% 80 70 39% 60 50 40 30 20 IA IB IIA IIB IIIA 10 0 Early stageNSCLC 5-year mortality rate from time to surgery Local relapse 30% 21% 10% Distant relapse70% 79% 90% Distant recurrence remains the major cause of treatment failure Mountain,Chest 97

  4. Early stageNSCLC How to reduce the risk of distant recurrence ? • Adjuvant treatment: Awaiting results of international trials (ANITA, IALT, NCI, BLT, ALPI) • Neoadjuvant treatment: Preoperative CT improves survival in IIIA patients and even earlier stages who can be completely resected Roth J. Lung Cancer 98; Rosell R. Lung Cancer 99; Depierre A. JCO 02; André F. JCO 00

  5. Navelbine + CDDP NAVELBINE 30 mg/m² D1, D8 CISPLATIN 80 mg/m²D1 every 3 weeks Spasova Phase II study n= 56 stage III pts OR54%Significantly longer survival pCR3 ptsfor responders (21 m. vs 9 m. p< 0.001) Complete32%Significantly longer survival for resectioncompletely resected patients (28 m. vs 11.5 m. p< 0.001) 1-YS59% 2-YS27% NAVELBINE allows survival improvement Spasova I et al. Eur. J. Cancer Vol 37 01

  6. Navelbine Experience2-3 drug combination with CDDP 9 studies, n= 257 pts Stage IIIA-B EFFICACY OR : 54-78% Resection : 43*-80% Complete Resection : 32-55% 1YS : 65-70% 2YS : 41% TOXICITIES NP Leucopenia G3 : 16% cy. Anemia G3 : 13% cy. NIP Feb. Neutropenia : 13% pts Alopecia G3 : 84% pts N/V G3 : 3% pts *all patients = IIIB

  7. A new approach with Navelbine:CT-RT preoperativetreatmentPhase II trial NVB 17.5 mg/m²/week CBDCA AUC 6 D1 RT 45 Gy Garst study n= 30 (stage IIIA) EFFICACY OR: 70% pCR: 10% Resection : 87% 1YS : 80% 2YS : 53% Garst, ASCO 2002

  8. Which competitors on the market ? • GEM • TXL • TXT

  9. Competitors: Review

  10. Recommended Schedules NVB 25-30 mg/m² D1, D8 + IFO 3 g/m² D1 CDDP 80 mg/m² D1 or CDDP 80 mg/m² D1 every 3 weeks every 3 weeks NP NIP during 3 to 6 cycles

More Related